Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07130786 · ClinicalTrials.gov registry record · Phase 2

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

A Phase 2 study of Seizures and Brain Metastases, Adult, sponsored by Ayal A. Aizer, MD.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
1
Study location

NCT07130786: Recruiting Phase 2 study of Seizures and Brain Metastases, Adult, sponsored by Ayal A. Aizer, MD.

NCT07130786 is a Phase 2 study of Seizures and Brain Metastases, Adult that is actively recruiting participants, run by Ayal A. Aizer, MD. The registered enrollment target is 150 participants, below the 931-participant average among 39 other Seizures trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07130786, a Phase 2 study of Seizures and Brain Metastases, Adult, is actively recruiting participants, sponsored by Ayal A. Aizer, MD.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which does not currently include prophylactic levetiracetam. Patients who enroll to this trial will be randomized to receive prophylactic levetiracetam or not receive prophylactic levetiracetam.

Primary Outcome

To determine whether seizure rate is lower in seizure-naïve patients with brain metastases in primary motor cortex with levetiracetam prophylaxis versus usual care of no ASM therapy.

Interventions

  • DRUG Levetiracetam (Keppra)

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-12-23
Est. Completion 2030-02
Phase Phase 2
Ayal A. Aizer, MD

2 total trials

What NCT07130786 shows while recruiting

NCT07130786 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 931-participant average among 39 other Seizures trials with a reported enrollment target (84% lower).

The record links to 5 conditions, with Seizures appearing as the primary indexed condition, and to 1 intervention - of which Levetiracetam (Keppra) is the first listed.

NCT07130786 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07130786 about?

NCT07130786 is a clinical study titled "Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases". This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which does not currently inc...

What is the current status of trial NCT07130786?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-12-23. Estimated completion is 2030-02.

What conditions does trial NCT07130786 study?

This clinical trial studies the following conditions: Seizures, Brain Metastases, Adult, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors, Primary Motor Cortex.

What interventions are being tested in trial NCT07130786?

The interventions under investigation include: Levetiracetam (Keppra) (DRUG).

Who is sponsoring clinical trial NCT07130786?

This trial is sponsored by Ayal A. Aizer, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07130786 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Seizures

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07130786's enrollment target sits among peer trials

150 18th of 39 higher than 22 of 39 other Seizures trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Seizures trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07130786, the US trial registry maintained by the National Library of Medicine. NCT07130786 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.